Literature DB >> 19176475

Limits on Medicare's ability to control rising spending on cancer drugs.

Peter B Bach1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19176475     DOI： 10.1056/NEJMhpr0807774

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  124 in total

Review 1.  Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.

Authors:  Rosa Lerose; Pellegrino Musto; Michele Aieta; Carla Papa; Alfredo Tartarone
Journal:  Eur J Clin Pharmacol       Date:  2011-12-14       Impact factor: 2.953

2.  How patient cost-sharing trends affect adherence and outcomes: a literature review.

Authors:  Michael T Eaddy; Christopher L Cook; Ken O'Day; Steven P Burch; C Ron Cantrell
Journal:  P T       Date:  2012-01

Review 3.  A way forward on the medically appropriate use of white cell growth factors.

Authors:  Thomas J Smith; Bruce E Hillner
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

4.  Improving quality and addressing the rising costs of cancer care: two birds, one stone.

Authors:  Jason Luke; Joshua Mirkin; Peter Bach
Journal:  J Oncol Pract       Date:  2011-10-18       Impact factor: 3.840

5.  International variability in the reimbursement of cancer drugs by publically funded drug programs.

Authors:  P K Cheema; S Gavura; M Migus; B Godman; L Yeung; M E Trudeau
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

6.  Finasteride and prostate cancer: a commentary.

Authors:  Channing J Paller; Thomas J Smith
Journal:  Oncologist       Date:  2012-06-20

7.  Targeted cancer therapies.

Authors:  Saurabh Aggarwal
Journal:  Nat Rev Drug Discov       Date:  2010-06       Impact factor: 84.694

8.  Medicare, ethics, and reflexive longevity: governing time and treatment in an aging society.

Authors:  Sharon R Kaufman; Lakshmi Fjord
Journal:  Med Anthropol Q       Date:  2011-06

9.  THE LOCAL INFLUENCE OF PIONEER INVESTIGATORS ON TECHNOLOGY ADOPTION: EVIDENCE FROM NEW CANCER DRUGS.

Authors:  Leila Agha; David Molitor
Journal:  Rev Econ Stat       Date:  2018-03-02

Review 10.  Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review.

Authors:  Daniel M Geynisman; Chun-Ru Chien; Fabrice Smieliauskas; Chan Shen; Ya-Chen Tina Shih
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.